With the goal of bringing the pandemic under control via equitable access to COVID-19 vaccines, a total of 172 countries are now engaged in discussions to participate in COVAX, according to the World Health Organization (WHO).
COVAX, co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the WHO, is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher- and lower-income countries.
So far, 80 self-financing countries have submitted non-binding expressions of interest to the Gavi-coordinated COVID-19 Vaccine Global Access Facility (COVAX Facility), joining 92 low- and middle-income economies that are eligible to be supported. The next step for the partnership is to confirm potential self-financing participants’ intent to participate by 31 August and turn these into binding commitments by 18 September.
Currently, COVAX has the world’s largest and most diverse COVID-19 vaccine portfolio - including nine candidate vaccines, with a further nine under evaluation. Conversations are underway with other major producers.
The goal of COVAX is to deliver 2 billion doses of vaccines by the end of 2021 and maintain a buffer of doses for emergency and humanitarian use.